Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Saved in:
| Title: | Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. |
|---|---|
| Authors: | Jain P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kanagal-Shamanna R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang S; Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ok CY; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Navsaria L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nastoupil L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee HJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tang G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yin CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Badillo M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel KM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Flowers C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vega F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang L; Department of Hemato-pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang ML; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E137-E140. Date of Electronic Publication: 2021 Feb 11. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
